ICYMI: AstraZeneca Profit, Revenue Lifted by Cancer Drugs
Bloomberg Businessweek
00:00
Reviving U.S. Pharmaceutical Manufacturing
This chapter explores the essential discussions around tariff talks and the push for returning pharmaceutical manufacturing to the U.S. It examines the implications on companies like AstraZeneca, as well as the broader landscape of innovation and competition in the global biotech industry. The conversation emphasizes the need for strategic investments and collaboration in order to maintain U.S. leadership in pharmaceutical innovation amidst rising global competitors.
Transcript
Play full episode
